Comparative Bleeding Risk in Patients with Atrial Fibrillation with Cancer versus Without Cancer from Nationwide Prospective Cohort

By sjmartinez • September 14, 2023

Kang KW, Shin D, Shin SY, Kim J, Choi EK, Cha MJ, Lee JM, Kim JB, Park J, Park JK, Kim TH, Uhm JS, Shim J, Lee YS, Park HW, Kim C, Joung B. Comparative Bleeding Risk in Patients with Atrial Fibrillation with Cancer versus Without Cancer from Nationwide Prospective Cohort. Int Heart J. 2023 Sep 13. doi: 10.1536/ihj.22-507. Epub ahead of print. PMID: 37704413.

Tags: Anti-coagulation, Composite events, Hematology/Oncology, Non-valvular atrial fibrillation, Publications

Trastuzumab deruxtecan and the evolving role of human epidermal growth factor receptor 2-targeted antibody-drug conjugates in breast and ovarian cancer

Thaker SK, Silverstein J, Konecny GE, Bardia A. Trastuzumab deruxtecan and the evolving role of human epidermal growth factor receptor 2-targeted antibody-drug conjugates in breast[...]

Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinoma

Chan SL, Finn RS, Edeline J, Ogasawara S, Knox JJ, Daniele B, Ryoo BY, Merle P, Bouattour M, Lim HY, Chao Y, Yau T, Haber[...]

First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial

Sun JM, Chao Y, Kim SB, Rha SY, Evans TRJ, Strickland AH, Wainberg Z, Chau I, Pelles-Avraham S, Ajani J, Malhotra R, Liu Q, Li[...]